Loading...
By Kristin J. Kelley
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The FDA warned on Thursday of prescription errors involving two drugs with similar brand names: the antidepressant Brintellix (vortioxetine) and the antiplatelet agent Brilinta (ticagrelor). Given that the two brand names begin with "Bri," they both may be displayed when providers select them in an electronic physician order entry system.
There have been 50 reports of confusion over the two brand names; 12 of these resulted in the wrong drug being dispensed. Thus far, the agency says, no patients have reported ingesting the wrong medication once it was dispensed, but clinicians are urged to use both brand and generic names in addition to the indication when prescribing either Brintellix or Brilinta.
Additional information about how to tell the two drugs apart is available in the linked drug safety communication.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
FDA drug safety communication (Free)
MedWatch adverse event reporting form (Free)
Background: Physician's First Watch coverage of another drug changing its brand name following confusion with other drugs (Free)